Company: BNBX
Filing Date: 2025-10-01
Form Type: 8-K
Source: 0001104659-25-095401
Chunk: 3

Company: BNB PLUS CORP.
Filing Date: 2025-10-01
Form: 8-K
Item: Item 3.02
Chunk 3
---
Item 3.02 Unregistered Sale of Equity Securities.

The information contained above in Item 1.01
relating to the issuance of the Common Stock, the Shares, the Common Warrants, the Prefunded Warrants, the Cryptocurrency Prefunded
Warrants, the Cryptocurrency Common Warrants, the Advisory Warrants and the Placement Agent Warrants is hereby incorporated by
reference into this Item 3.02.

Neither this Current Report on Form 8-K nor any
exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 28, 2025,
Judith Murrah informed the Company of her intention to step down from her positions as the Company’s Chief Executive Officer and
President effective September 29, 2025. As described in the Initial 8-K, Ms. Murrah’s title is Strategic Transition Advisor and
she will remain as Chairperson of the Company’s Board of Directors (the “ Board”) until a new Chairperson is duly confirmed
by the Nominating Committee of the Board and thereafter as a member of the Board. Ms. Murrah’s resignation is not the result of
any dispute or disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices.
In connection with Ms. Murrah’s resignation, Ms. Murrah and the Company entered into a separation agreement dated September 29,
2025 (the “ Separation Agreement”). The Company previously disclosed the Separation Agreement in the Initial 8-K.

On September 28, 2025,
the Board approved the appointment of Clay D. Shorrock, current Chief Legal Officer of the Company and President of LineaRx, Inc., the
Company’s biotherapeutics subsidiary, as Chief Executive Officer of the Company, effective September 29, 2025. Mr. Shorrock assumed
the role of Chief Executive Officer from Judith Murrah. The Company previously disclosed the appointment of Mr. Shorrock in the Initial
8-K.

On September 28, 2025,
the Board approved new Employment Agreements (together, the “ Employment Agreements”) with Mr. Shorrock and Beth Jantzen, Chief
Financial Officer of the Company. The Company previously disclosed the